Dysmenorrhea

Active Ingredient: Niflumic acid

Indication for Niflumic acid

Population group: women, only adolescents (12 years - 18 years old) , adults (18 - 65 years old)
Therapeutic intent: Curative procedure

Immediate relief from pain during menstruation (dysmenorrhea).

For this indication, competent medicine agencies globally authorize below treatments:

250 mg 2-3 times daily for 4-5 days

For:

Dosage regimens

Oral, 250 milligrams niflumic acid, 2 to 3 times daily.

250 mg 3-4 times daily for 4-5 days

For:

Dosage regimens

Oral, 250 milligrams niflumic acid, 3 to 4 times daily, over the duration of 4 to 5 days.

Active ingredient

Niflumic acid

Niflumic acid is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.

Read more about Niflumic acid

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.

⇈